Diuretic Physiology and Diuretic Resistance

A diuretic response begins with drug delivery and ends with a change in what leaves the body. Impaired absorption or secretion, increased sodium recovery, declining filtered supply, and retention between drug effects can weaken the response. Useful decongestion requires sodium and water removal to improve the congested state while preserving organ perfusion.

49.1 Diuresis, Natriuresis, and Decongestion Are Different Outcomes

Diuresis is increased urine volume. Natriuresis is increased urinary sodium excretion. Decongestion is improvement in the abnormal accumulation or distribution of fluid and the pressures or organ effects associated with it. These outcomes often accompany one another, but none is a complete substitute for the others.

Urine can increase because more water accompanies sodium salts, because nonelectrolyte solutes retain water in the tubule, or because collecting-duct water permeability falls. The composition determines what the volume means for sodium balance. A large water output can coexist with limited sodium removal, while a smaller, sodium-rich output can remove more sodium.

Loop diuretics inhibit the apical sodium–potassium–chloride cotransporter, NKCC2, in the thick ascending limb. Reduced salt reabsorption increases downstream delivery. Because this segment normally removes salt with little water, inhibition also weakens the medullary concentrating system. Final water excretion nevertheless depends on downstream transport, solute composition, antidiuretic signaling, and water availability.

The final urinary effect is a whole-nephron result. Sodium escaping an inhibited loop segment can be reabsorbed in the distal convoluted tubule, connecting tubule, and collecting system. A transporter can be inhibited successfully while the increase in final sodium excretion remains modest. Conversely, an apparently weak response may begin with inadequate drug delivery before the target is reached.

Diuretic resistance therefore needs an explicit outcome and interval. It may describe limited sodium excretion for a given exposure, failure to achieve negative sodium balance, or persistent congestion despite treatment. Those descriptions are related but identify different problems. High sodium intake can prevent negative balance despite a strong acute renal response; persistent venous pressure can also reflect cardiac or mechanical disease beyond retained fluid.

Substantial urine production can reduce effective preload faster than interstitial fluid refills the circulation. Another patient can improve renal drainage as congestion falls. Drug response, continued need for removal, and tolerance require separate assessment.

49.2 Loop Diuretics Must Reach the Tubular Lumen

The relevant concentration for loop inhibition is at the luminal side of the transport system. A plasma concentration or administered amount does not directly establish this exposure. Furosemide and related organic anions are extensively protein-bound, limiting delivery by glomerular filtration; proximal tubular secretion is an important route into tubular fluid.

Drug moves from peritubular blood into proximal tubular cells and then across the apical membrane into the lumen. Basolateral organic anion transporters, including OAT1 and OAT3, contribute to uptake. The transport process depends on functioning cells, appropriate electrochemical coupling, renal delivery, and competition from other organic anions. Subsequent luminal flow carries drug toward its target.

Odlind and Beermann studied six healthy subjects during furosemide infusion and inhibited tubular secretion with probenecid. Plasma furosemide increased while its urinary delivery and saluretic effect decreased. The experiment directly illustrates why a higher circulating drug concentration need not mean stronger luminal action. It does not supply a clinical probenecid challenge or a general response percentage for kidney disease. 1

Vallon and colleagues combined transporter-expression experiments with Oat-knockout mice. Loss of either OAT1 or OAT3 impaired normal furosemide handling and shifted natriuretic responses. These preparations identify transport contributions; they do not quantify transporter activity in an individual critically ill patient. 2

Renal dysfunction can reduce the functioning secretory mass and increase competition from retained organic anions. Impaired renal delivery may add another limitation. These mechanisms concern access to the site, rather than proving that NKCC2 has become intrinsically insensitive. Thiazide-type organic anions also depend substantially on tubular secretion, whereas drugs acting through intracellular mineralocorticoid receptors have different delivery requirements.

A urinary drug concentration, where measured in research, still requires flow and timing to estimate delivery rate. A dilute concentration during brisk flow may represent substantial drug passage. Moreover, final urinary recovery is a practical surrogate for luminal delivery, not a continuous measurement of free drug concentration at every transporter.

49.3 Absorption, Binding, and Kidney Dysfunction Alter Exposure Differently

Oral delivery adds dissolution, gastrointestinal transit, absorption, and first passage before renal secretion can occur. Congestion, impaired perfusion, food, formulation, and gastrointestinal dysfunction can modify the time course. Delayed absorption can blunt a peak even when the total amount eventually absorbed changes little. Different loop agents do not have identical oral pharmacokinetics.

Vasko and colleagues studied oral furosemide in 11 patients during decompensated heart failure and after compensation. Absorption was slower during decompensation, whereas the area under the serum concentration–time curve did not change significantly. The findings support a timing problem rather than a universal claim that decompensation prevents absorption altogether. 3

Protein binding introduces another distinction. Albumin influences the circulating free fraction, distribution, clearance, and presentation of drug to the kidney. Reduced albumin does not necessarily increase useful tubular exposure simply because more drug is unbound. Increased distribution outside the vascular compartment and altered elimination can counter that expectation. Albumin appearing in tubular fluid can also bind drug, but its quantitative importance varies by disease and exposure.

Charokopos and colleagues studied 208 outpatients with heart failure and validated findings in 60 inpatients. Across the albumin ranges represented, serum albumin did not explain urinary diuretic delivery, and urinary albumin did not explain diuretic efficiency after relevant adjustment. This limits treating albumin as a universal explanation for resistance; it does not settle every circumstance of profound hypoalbuminemia or nephrotic disease. 4

Reduced glomerular filtration rate, or GFR, adds both delivery and response limitations. Less functioning kidney may secrete less drug into the lumen, and less sodium is filtered for potential excretion. Even if a substantial fraction of filtered sodium escapes, the absolute amount can remain limited. Prolonged plasma persistence does not guarantee sufficient luminal action in the remaining nephrons.

Distinguishing impaired absorption, reduced secretion, altered binding, and downstream compensation requires the response time course and renal and circulatory assessment. Albumin or creatinine alone cannot locate the entire defect.

49.4 Threshold and Ceiling Describe a Response Curve, Not Fixed Doses

At low luminal exposure, increasing drug may produce little detectable natriuresis. Across a steeper part of the exposure–response curve, a comparable increase can produce a much larger effect. At sufficiently high exposure, the instantaneous response approaches a plateau because the susceptible transport system and available sodium supply impose limits.

Threshold describes the exposure range needed for an appreciable effect, rather than a molecular switch. Ceiling describes a plateau under specified conditions. Disease, delivery, adaptation, and the measured endpoint can reshape the curve.

A dimensionless illustrative model makes the shape visible:

Here c is luminal concentration divided by an assumed concentration producing half-maximal effect. Both c and the resulting fraction have no units. The exponent of two is chosen for teaching; this is not a fitted patient curve or a real exposure target.

With c of 0.5, the fraction is 0.25 ÷ 1.25 = 0.20. At c of 2, it is 4 ÷ 5 = 0.80; at c of 4, 16 ÷ 17 ≈ 0.94. Increasing exposure near the middle produces a larger gain than extending an already near-maximal response. These fractions do not predict urine volume or an administered dose.

Time remains important after a peak response plateaus. A larger exposure may prolong the period during which useful luminal concentrations persist, increasing cumulative excretion without raising the peak much. Continuous delivery can reduce troughs, but an inadequate infusion can also remain below effective exposure. Pharmacological plausibility does not determine the best administration strategy for every population.

DOSE randomized 308 patients with acute decompensated heart failure in a factorial comparison of administration method and intensity. The principal symptom and creatinine comparisons were not significantly different; higher intensity produced greater diuresis and some favorable secondary measures with more transient worsening renal function. Its selected heart-failure population and protocols do not establish one universally superior method, particularly in shock. 5

49.5 Retention Between Drug Effects Can Offset Acute Sodium Loss

An acute natriuretic episode is only part of a day's balance. When luminal drug exposure falls, sodium reabsorption can recover or become particularly avid. Reduced effective arterial filling, sympathetic and renin–angiotensin–aldosterone signaling, altered delivery, and the prevailing sodium intake influence this period.

Postdiuretic sodium retention describes increased conservation after the active natriuretic period. It differs from the immediate absence of a drug effect: the kidney can actively offset earlier losses. The balance achieved across repeated exposure therefore depends on both the active response and what happens between responses.

Wilcox and colleagues studied six healthy subjects during different sodium intakes. Compensatory retention between furosemide effects could offset the acute natriuresis; the relationship between intake and cumulative sodium loss differed from the magnitude of the short-term response. These controlled balance observations identify a mechanism rather than prescribing an intake or schedule for critically ill patients. 6

Consider an illustrative collection divided into two periods. Sodium excretion is 150 mmol during the first six hours and only 30 mmol during the remaining 18 hours. Total daily renal sodium loss is 150 + 30 = 180 mmol. If absorbed and parenteral sodium input is 200 mmol and nonrenal loss is negligible, body sodium balance is 200 − 180 = +20 mmol.

The kidney produced an impressive early response, yet the body retained sodium over the complete interval. These quantities are assumed for teaching, not recommended inputs or targets. Unmeasured gastrointestinal loss, incomplete collection, or a changing treatment interval would alter the accounting.

This explains why counting administrations or recording a few hours of urine can misclassify the overall result. Nutrition, carriers, flushes, and other sodium sources belong in the input term. Retention can persist even when the visible diet appears modest.

The mechanism also explains why duration and intervals matter independently of peak intensity. However, prolonging exposure changes electrolyte loss and circulatory stress as well as sodium excretion. The balance problem must be connected to ongoing congestion and tolerance rather than solved by pursuing an isolated daily amount.

49.6 Distal Adaptation Recovers Sodium Released Upstream

Repeated loop inhibition increases sodium delivery to downstream segments. These segments possess transport reserve and can increase reabsorption acutely through existing transport systems. With sustained exposure, altered transporter abundance and structural adaptation can increase their capacity further.

The distal convoluted tubule reabsorbs sodium chloride through NCC, the sodium–chloride cotransporter. Later electrogenic sodium entry through epithelial sodium channels, or ENaC, provides another route. Hormonal regulation, potassium status, luminal flow, and delivery determine how much of the additional load is recovered. The remaining sodium that reaches urine is therefore not a direct assay of loop inhibition alone.

Ellison, Velázquez, and Wright used micropuncture, microperfusion, and morphometry in rats to examine chronic changes in sodium chloride delivery. Furosemide exposure with replacement of losses increased distal transport capacity and produced structural changes in the distal convoluted tubule. This establishes adaptation in a controlled animal preparation, not an identical anatomical response in every human treated with a loop drug. 7

Rao and colleagues studied 128 patients with heart failure using endogenous lithium handling as a physiological proxy for sodium exit from proximal and loop segments. The increase in final sodium excretion was much smaller than the estimated upstream release, supporting substantial compensatory distal recovery. The inference relies on clearance assumptions; it is not direct sampling of each human tubular segment. 8

Drug delivery can still limit upstream inhibition. Where sodium escape is substantial, downstream recovery becomes a plausible explanation for limited final excretion. Adaptation protects volume during salt loss but can oppose decongestion in heart failure.

More recently, Rao and colleagues randomized 103 patients with resistant acute heart failure to loop intensification or adjunct chlorothiazide. Chlorothiazide produced greater improvement in six-hour natriuresis, but lithium-derived mechanism categories did not identify preferential response. Demonstrating regional sodium recovery therefore did not establish a successful treatment-selection rule, and the study did not test survival benefit. 9

Complementary blockade remains physiologically coherent, but a spot urine value or clearance category cannot guarantee the most effective or tolerable combination.

49.7 Proximal Blockade Changes Sodium and Bicarbonate Delivery

Proximal sodium reabsorption is coupled to multiple solutes, including bicarbonate. Secreted hydrogen combines with filtered bicarbonate in the lumen; carbonic anhydrase facilitates conversion through carbon dioxide and water, allowing bicarbonate reclamation across the epithelial cell. Basolateral transport returns bicarbonate and sodium toward the circulation.

Acetazolamide inhibits carbonic anhydrase and reduces this coupled reclamation. More bicarbonate and associated sodium remain in tubular fluid, increasing downstream delivery. The urine becomes more alkaline during bicarbonate loss, while the body can develop a metabolic acidosis. Urine pH and systemic pH therefore need not move in the same direction.

Acting proximally can complement loop inhibition by increasing sodium delivery to a segment whose reabsorptive pathway is also blocked. The effect still depends on filtered substrate and subsequent transport. As bicarbonate availability changes and other segments compensate, the response need not remain constant. Reduced kidney function and evolving acid–base conditions alter both efficacy and adverse-effect potential.

ADVOR evaluated adding acetazolamide to a standardized loop strategy in acute decompensated heart failure with clinical volume overload. Its primary analysis included 515 patients after four randomized patients were not assessable. Successful early decongestion occurred more often with acetazolamide, while death or heart-failure rehospitalization over three months was not significantly reduced. The trial evaluated a combined strategy in its selected population, not isolated proximal physiology or a universal ICU intervention. 10

The distinction between a transport rationale and the trial result matters. Greater delivery provides one plausible explanation for improved decongestion, but the intervention also changes bicarbonate handling, renal feedback, and the time course of treatment. The observed effect cannot be assigned to one component with certainty.

Likewise, an elevated bicarbonate concentration does not independently prove that proximal sodium transport is the sole resistance mechanism. The acid–base state can reflect ventilation, chloride and potassium balance, and earlier treatments. Integrating these observations identifies a coherent hypothesis; it does not convert bicarbonate into a stand-alone prescription.

49.8 Distal Blockade Has Complementary Effects and Added Costs

Thiazide and thiazide-like drugs inhibit NCC in the distal convoluted tubule. When loop inhibition increases delivery to this site, blocking distal recovery can produce more sodium excretion than the loop effect alone. The combination targets transport in series rather than assuming that the effects are independent and merely additive.

The result depends on how much sodium reaches the distal segment and how much transport capacity remains there. Inadequate upstream drug delivery, very limited filtration, or strong recovery further downstream can still constrain the response. The phrase sequential nephron blockade describes complementary sites; it does not guarantee a particular excretion rate or imply one required timing sequence for all drugs.

CLOROTIC randomized 230 patients with acute heart failure to hydrochlorothiazide or placebo added to intravenous furosemide. The combination improved weight loss, one coprimary endpoint, without a significant difference in patient-reported dyspnea, the other. Impaired renal function occurred more often. Recruitment ended below the intended sample size, and the findings do not establish improved survival from the combination. 11

Later sodium transport can also be modified through ENaC blockade or antagonism of mineralocorticoid signaling. These approaches reduce an electrogenic pathway coupled to potassium secretion. Mineralocorticoid antagonists additionally alter transcriptional signaling and have effects beyond an immediate urine response. Their disease-specific clinical benefits cannot be reduced to a single acute natriuretic mechanism.

Suppressing late sodium entry can reduce potassium secretion, creating hyperkalemia risk when excretory capacity is limited. This differs from the increased potassium loss that can accompany enhanced delivery with loop or thiazide drugs. Combining transport effects can therefore change which adverse effect dominates rather than simply making treatment stronger.

Complementarity supports a physiological explanation for selected combinations, while outcome trials and repeated assessment establish their practical limits. A more pronounced renal response is not automatically a more useful response if it produces electrolyte disturbance, acid–base deterioration, or a loss of perfusion exceeding the relief of congestion.

49.9 Electrolyte and Acid–Base Effects Follow the Transport Pathways

Loop and thiazide effects can increase sodium delivery and flow through potassium-secreting distal segments. Electrogenic sodium absorption, aldosterone signaling, apical potassium channels, and the available potassium gradient then determine secretion. Potassium loss is a downstream consequence of the combined transport environment rather than a fixed quantity accompanying every liter of urine.

Magnesium depletion can intensify this problem, but its effect remains conditional. Maeoka and colleagues found that magnesium restriction alone lowered ENaC activity and did not cause hypokalemia in their mouse preparation. Combined sodium and magnesium restriction preserved ENaC activity and increased secretion through renal outer medullary potassium channels, or ROMK, with hypokalemia. The study reinforces the need for both channel availability and a driving force; it is not a human replacement protocol. 12

Loop inhibition also reduces the lumen-positive electrical environment supporting paracellular calcium and magnesium reabsorption in the thick ascending limb. Urinary losses can increase. Thiazide effects differ: urinary calcium commonly decreases, while magnesium conservation can deteriorate. These different consequences arise from the sites and adaptations involved, not a universal class effect on all divalent ions.

Chloride depletion, potassium depletion, increased distal delivery, and hormonal responses can help generate or maintain metabolic alkalosis during salt loss. Reduced effective circulating volume can augment bicarbonate reclamation, but volume contraction is not a complete explanation in every patient. Chloride and potassium balance, filtration, and distal hydrogen secretion also matter.

Acetazolamide instead promotes bicarbonate loss and can contribute to metabolic acidosis. Suppression of late electrogenic sodium transport can reduce potassium and hydrogen excretion, particularly when kidney function is impaired. The net acid–base result depends on the combination of drugs, prior abnormalities, and ongoing nonrenal inputs and losses.

Thiazide-associated impairment of urinary dilution can interact with water intake and antidiuretic signaling to lower serum sodium. Sodium loss alone does not determine its concentration. Serial sodium, potassium, magnesium, bicarbonate, and relevant calcium measurements therefore assess different physiological consequences; a single reassuring result cannot represent them all.

49.10 Timed Sodium Excretion Clarifies the Observed Response

A urine sodium concentration is an amount per volume. Convert it to an excretion rate by pairing it with urine flow over a comparable interval:

U_Na is urine sodium in mmol/L. Flow in L/hour gives mmol/hour. With an illustrative U_Na of 70 mmol/L and flow of 0.20 L/hour, excretion is 70 × 0.20 = 14 mmol/hour. If sustained for a representative six-hour collection, the amount is 14 × 6 = 84 mmol. The extrapolation requires that the measured composition and flow represent that interval.

A spot sample near peak action cannot automatically represent the following day. Bladder mixing, collection delays, changing exposure, renal function, and intake affect interpretation. Timed collections reduce some uncertainties but introduce others, including incomplete recovery or mismatched start and stop times.

Urine volume, net fluid balance, weight, symptoms, and congestion findings add complementary information. Weight can be affected by measurement conditions and nonfluid changes; recorded balance can omit input and losses. Neither is a perfect independent standard. Sodium excretion more directly describes the transport outcome, while external balance determines whether body sodium actually falls.

PUSH-AHF randomized 310 patients with acute heart failure in a single-center, open-label strategy trial. A natriuresis-guided approach increased 24-hour sodium excretion compared with usual care, but did not significantly reduce the other primary endpoint of death or heart-failure rehospitalization at 180 days. The tested algorithm altered treatment intensity and used repeated assessments; it was not a trial of measuring urine sodium alone. 13

The result supports a measurable change in renal response without proving that every increment in natriuresis improves later outcomes. It also does not establish a universal urine sodium threshold for shock, chronic kidney disease, or every ICU fluid problem. Interpretation remains conditional on congestion, inputs, exposure, and perfusion.

A useful measurement should resolve a question: whether exposure produced sodium loss, whether that loss exceeded intake, and whether the resulting clinical trajectory is beneficial. These questions require related but distinct observations.

49.11 More Urine Does Not Prove Renal Recovery or Circulatory Tolerance

Diuretics can increase urine by changing transport in functioning nephrons without reversing the disease that impaired filtration. Increased output is therefore evidence of a response, not proof that tubular injury has resolved or that filtration has recovered. A poor response can likewise reflect several delivery and transport limitations rather than one diagnosis.

Cantarovich and colleagues randomized 338 patients with established acute renal failure requiring dialysis to furosemide or placebo. The drug increased achievement of substantial urine output, but survival and renal recovery did not significantly improve. This separates an excretory effect from disease modification in that population; it does not negate the possible value of controlling fluid accumulation. 14

Creatinine requires equally careful interpretation during removal. Filtration can change through renal hemodynamics and effective circulating volume, while distribution and marker kinetics affect the serum concentration. A rise does not by itself establish structural injury, and it cannot safely be dismissed merely because edema is improving.

Rao and colleagues analyzed a CARRESS-HF biomarker substudy of patients with acute decompensated heart failure and preexisting worsening renal function. Further creatinine worsening during intensive volume removal was associated with increases in tubular injury markers, while marker increases were also associated with greater decongestion and better 60-day creatinine recovery. These observational associations within a selected trial cohort do not make a creatinine rise proof of structural injury, establish universal harmlessness, or justify continuing removal in every patient. 15

Tolerance concerns the combined circulation and tissues. Vascular refill from the interstitium may sustain preload as fluid leaves, or removal may outpace refill. Reduced venous pressure can improve drainage while declining arterial inflow impairs perfusion. The net result depends on which change dominates and how cardiac function responds.

Assess congestion together with pressure, forward flow, perfusion, electrolytes, and renal trajectory. Persistent edema does not establish tolerance of further removal, and creatinine alone does not establish treatment failure. Explain the direction and timing of the whole response.

49.12 Integrate Drug Access, Sodium Balance, and Clinical Purpose

Consider two illustrative days with measured, complete urine collections. On each day the patient receives 150 mmol of absorbed or parenteral sodium, loses 10 mmol nonrenally, and produces 3 L of urine. Total water input is 2.5 L and nonrenal water loss is 0.5 L. These assumed quantities isolate the importance of composition.

On the first day, the collected urine has an average sodium concentration of 40 mmol/L. Renal sodium loss is 3 × 40 = 120 mmol, and external sodium balance is 150 − 120 − 10 = +20 mmol. Water balance is 2.5 − 3 − 0.5 = −1 L. The body loses water while retaining sodium.

On the second day, the same urine volume has an average sodium concentration of 90 mmol/L. Renal loss is 3 × 90 = 270 mmol, giving sodium balance 150 − 270 − 10 = −130 mmol, with the same modeled water balance of −1 L. Identical urine volume and net water loss accompany very different sodium balances. These are measured-interval examples, not extrapolations from one spot specimen or treatment targets.

If congestion remains problematic after the first day, examine where the limitation could arise. Delayed absorption, inadequate secretion, short effective exposure, distal recovery, and sodium input are different hypotheses. A change in administration, exposure, or complementary transport blockade can test a hypothesis, but each also changes adverse-effect potential. The current state determines which explanation is plausible.

After any change, reassess more than urine volume. Determine whether sodium excretion changed, whether cumulative balance became negative, whether tissue or venous congestion improved, and whether perfusion remained adequate. Recheck electrolyte and acid–base effects as the excretory pattern evolves. A previous response cannot guarantee the same response after stores, kidney function, or circulatory conditions change.

Establish the removal problem, identify the likely delivery or transport limitation, quantify losses, and assess benefit and tolerance. Mechanistic precision helps interpret trials within the populations and strategies actually studied.

References

1. Odlind B, Beermann B. Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther. 1980;27:784–790. doi:10.1038/clpt.1980.111

2. Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK. Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008;294:F867–F873. doi:10.1152/ajprenal.00528.2007

3. Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985;102:314–318. doi:10.7326/0003-4819-102-3-314

4. Charokopos A, Griffin M, Rao VS, et al. Serum and urine albumin and response to loop diuretics in heart failure. Clin J Am Soc Nephrol. 2019;14:712–718. doi:10.2215/CJN.11600918

5. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805. doi:10.1056/NEJMoa1005419

6. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med. 1983;102:450–458. PubMed

7. Ellison DH, Velázquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat: structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest. 1989;83:113–126. doi:10.1172/JCI113847

8. Rao VS, Planavsky N, Hanberg JS, et al. Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol. 2017;28:3414–3424. doi:10.1681/ASN.2016111178

9. Rao VS, Cox ZL, Ivey-Miranda JB, et al. Loop diuretic dose intensification versus adjuvant thiazide for diuretic resistance in acute heart failure: mechanistic randomized controlled trial. J Am Soc Nephrol. 2026;37:533–544. doi:10.1681/ASN.0000000887

10. Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185–1195. doi:10.1056/NEJMoa2203094

11. Trullàs JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023;44:411–421. doi:10.1093/eurheartj/ehac689

12. Maeoka Y, Duan XP, Zhang CB, et al. Hypomagnesaemia-associated hypokalaemia requires activation of both ENaC and ROMK. J Physiol. 2025;603:7365–7382. doi:10.1113/JP287704

13. ter Maaten JM, Beldhuis IE, van der Meer P, et al. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nat Med. 2023;29:2625–2632. doi:10.1038/s41591-023-02532-z

14. Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VLM. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis. 2004;44:402–409. doi:10.1053/j.ajkd.2004.05.021

15. Rao VS, Ahmad T, Brisco-Bacik MA, et al. Renal effects of intensive volume removal in heart failure patients with preexisting worsening renal function. Circ Heart Fail. 2019;12(6):e005552. doi:10.1161/CIRCHEARTFAILURE.118.005552